SynthesisTherapeutic advances in cardiovascular disease
Epidemiology of infective endocarditis before
Synthesis in Therapeutic advances in cardiovascular disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Risk of Infective Endocarditis Following Invasive Dental Procedures: A Systematic Review and Meta-Analysis.Public health reviews · 2024Pooled it
- Antibiotic prophylaxis for preventing bacterial endocarditis following dental procedures.The Cochrane database of systematic reviews · 2022Pooled it
- Pooled it
- Infective Endocarditis on Aortic Valve: From Diagnosis to Cardiac Surgical Intervention-Narrative Review.Journal of clinical medicine · 2026Review
- Current Surgical Approaches to Managing Infective Endocarditis With Aortic Root Abscess.Reviews in cardiovascular medicine · 2026Review
- The Biological Cost of Every Heartbeat: Imaging-Derived Cardiovascular Vulnerability in Infective Endocarditis.International journal of molecular sciences · 2026Article
- ENDOCOR: a nationwide consortium of endocarditis teams-initiating a registry for infective endocarditis within the Netherlands Heart Registration.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2025Article
- Infective Endocarditis in Special Populations: Epidemiology, Diagnostic Challenges, and Management Strategies.Cureus · 2025Review
- Antibiotics in Mucogingival Surgery for Recession Treatment: A Narrative Review.Antibiotics (Basel, Switzerland) · 2025Review
- Molecular diagnosis of infective endocarditis from culture-negative valve samples in a tertiary hospital in Iran.Microbiology spectrum · 2025Article
- Early and Long-Term Outcomes of Patients Undergoing Surgery for Native and Prosthetic Valve Endocarditis: The Role of Preoperative Neutrophil-to-Lymphocyte Ratio, Neutrophil-to-Platelet Ratio, and Monocyte-to Lymphocyte Ratio.Journal of clinical medicine · 2025Article
- Clinical aspects and short-term prognosis in a cohort of patients with infective endocarditis, São Paulo, Brazil.Revista da Escola de Enfermagem da U S P · 2025Article
- Increase in Oral Streptococcal Endocarditis Among Moderate-Risk Patients: Impact of Guideline Changes on Endocarditis Prevention.JACC. Advances · 2024Article
- Emerging and Re-Emerging Pathogens in Valvular Infective Endocarditis: A Review.Pathogens (Basel, Switzerland) · 2024Review
- Imaging in Infective Endocarditis-Current Opinions and Trends in Cardiac Computed Tomography.Diagnostics (Basel, Switzerland) · 2024Review
- Epidemiological differences, clinical aspects, and short-term prognosis of patients with healthcare-associated and community-acquired infective endocarditis.Infection prevention in practice · 2024Article
- Temporal trends in incidence, patient characteristics, microbiology and in-hospital mortality in patients with infective endocarditis: a contemporary analysis of 86,469 cases between 2007 and 2019.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Novel Diagnostic Methods for Infective Endocarditis.International journal of molecular sciences · 2024Review
- Endovascular aspiration of native tricuspid valve vegetation using INARI catheter in a patient with methicillin-sensitiveRadiology case reports · 2024Article
- Eustachian Valve Endocarditis: A Case Report and Literature Review.Journal of community hospital internal medicine perspectives · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAll major international guidelines for the management of infective endocarditis (IE) have undergone major revisions, recommending antibiotic prophylaxis (AP) restriction to high-risk patients or foregoing AP completely. We performed a systematic review to investigate the effect of these guideline changes on the global incidence of IE.
methodsElectronic database searches were performed using Ovid Medline, EMBASE and Web of Science. Studies were included if they compared the incidence of IE prior to and following any change in international guideline recommendations. Relevant studies fulfilling the predefined search criteria were categorized according to their inclusion of either adult or pediatric patients. Incidence of IE, causative microorganisms and AP prescription rates were compared following international guideline updates.
resultsSixteen studies were included, reporting over 1.3 million cases of IE. The crude incidence of IE following guideline updates has increased globally. Adjusted incidence increased in one study after European guideline updates, while North American rates did not increase. Cases of IE with a causative pathogen identified ranged from 62% to 91%. Rates of streptococcal IE varied across adult and pediatric populations, while the relative proportion of staphylococcal IE increased (range pre-guidelines 16-24.8%, range post-guidelines 26-43%). AP prescription trends were reduced in both moderate and high-risk patients following guideline updates. DISCUSSION: The restriction of AP to only high-risk patients has not resulted in an increase in the incidence of streptococcal IE in North American populations. The evidence of the impact of AP restriction on IE incidence is still unclear for other populations. Future population-based studies with adjusted incidence of IE, AP prescription rates and accurate pathogen identification are required to delineate findings further in these other regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.